- Home
- NCPL vs APRE Comparison
NCPL vs APRE Comparison
Compare NCPL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- APRE
- Stock Information
- Founded
- NCPL 1984
- APRE 2006
- Country
- NCPL United States
- APRE United States
- Employees
- NCPL N/A
- APRE N/A
- Industry
- NCPL Investment Managers
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCPL Finance
- APRE Health Care
- Exchange
- NCPL Nasdaq
- APRE Nasdaq
- Market Cap
- NCPL 9.1M
- APRE 9.4M
- IPO Year
- NCPL N/A
- APRE 2019
- Fundamental
- Price
- NCPL $2.34
- APRE $1.54
- Analyst Decision
- NCPL
- APRE Strong Buy
- Analyst Count
- NCPL 0
- APRE 1
- Target Price
- NCPL N/A
- APRE $20.00
- AVG Volume (30 Days)
- NCPL 205.7K
- APRE 32.9K
- Earning Date
- NCPL 09-11-2025
- APRE 11-06-2025
- Dividend Yield
- NCPL N/A
- APRE N/A
- EPS Growth
- NCPL N/A
- APRE N/A
- EPS
- NCPL N/A
- APRE N/A
- Revenue
- NCPL $869,460.00
- APRE $841,012.00
- Revenue This Year
- NCPL $739.37
- APRE N/A
- Revenue Next Year
- NCPL N/A
- APRE N/A
- P/E Ratio
- NCPL N/A
- APRE N/A
- Revenue Growth
- NCPL N/A
- APRE N/A
- 52 Week Low
- NCPL $1.41
- APRE $1.41
- 52 Week High
- NCPL $8.75
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- NCPL 49.13
- APRE 43.27
- Support Level
- NCPL $1.77
- APRE $1.49
- Resistance Level
- NCPL $2.34
- APRE $1.66
- Average True Range (ATR)
- NCPL 0.19
- APRE 0.08
- MACD
- NCPL 0.11
- APRE 0.00
- Stochastic Oscillator
- NCPL 74.03
- APRE 27.00
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.